Table 5.
Scenario analysis results
| Results for carbapenem-sparing scenario where non-carbapenem drugs are given precedence | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
| Total costs per patient (USD 2015) | $36,416 | $36,038 | $378 |
| Total QALYs (discounted) per patient | 9.19 | 9.13 | 0.06 |
| Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | $6020 | ||
| Results using only nosocomial isolates | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
| Total costs per patient (USD 2015) | $42,737 | $42,358 | $378 |
| Total QALYs (discounted) per patient | 12.37 | 12.27 | 0.10 |
| Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | - | - | $3825 |
| Results for high risk patients (aged 65 years, requiring an ICU stay or catheter-associate infection) using nosocomial isolates | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
| Total costs per patient (USD 2015) | $37,947 | $37,557 | $390 |
| Total QALYs (discounted) per patient | 10.10 | 10.03 | 0.07 |
| Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | - | - | $6037 |
| Results when lifetime health care expenditure for health survivors is excluded | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
| Total costs per patient (USD 2015) | $7762 | $7583 | $179 |
| Total QALYs (discounted) per patient | 9.19 | 9.13 | 0.06 |
| Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | - | - | $2842 |
QALY Quality-adjusted life year